{"id":"W1992627136","doi":"10.1053/j.ajkd.2009.08.019","title":"Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group","year":2009,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Abbott Laboratories","keywords":"Medicine; Adalimumab; Renal function; Tolerability; Focal segmental glomerulosclerosis; Pharmacokinetics; Kidney disease; Internal medicine; Urology; Dosing; Proteinuria; Pharmacology; Adverse effect; Gastroenterology; Kidney; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001634905,0.001672689,0.002200101,0.0003050952,0.0004329436,0.001209642,0.0006792432,0.001629263,0.003316852],"category_scores_gemma":[0.001189924,0.0004781648,0.001492767,0.0002226808,0.0005657123,0.0009643431,0.0003134975,0.003241506,0.001136376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005092472,"about_ca_system_score_gemma":0.000801716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009198147,"about_ca_topic_score_gemma":0.002130453,"domain_scores_codex":[0.999572,0.0002349734,0.00001433533,0.00004916582,0.00004110779,0.00008852556],"domain_scores_gemma":[0.9992881,0.0002644499,0.0001111972,0.00004453852,0.00004447285,0.0002473599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8530279,0.01432176,0.002328225,0.001379866,0.002239101,0.000288258,0.0001867916,0.002448713,0.01329606,0.0006477124,0.01792657,0.09190908],"study_design_scores_gemma":[0.9097323,0.07734682,0.005994972,0.00007721061,0.0006174449,0.0002445861,0.00003963772,0.001077685,0.001424339,0.0004346427,0.002979227,0.00003113685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9615936,0.01813002,0.001310096,0.003358716,0.001087615,0.002174253,0.004698253,0.0003105201,0.007336825],"genre_scores_gemma":[0.9671577,0.00876572,0.002959444,0.004974241,0.001244889,0.002462067,0.004691306,0.00008805162,0.007656627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003316852,"threshold_uncertainty_score":0.01109594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01623586316231407,"score_gpt":0.3107127171153414,"score_spread":0.2944768539530274,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}